RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
Study sponsor: Reviva Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2013-03Actual
Enrollment · participants234Actual
Source updated2025-08-08Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.